Estatinas, uso racional en el tratamiento de la dislipoproteinemia

Illnait Ferrer, José.
Rev. cuba. med. gen. integr ; 25(2)abr.-jun. 2009. tab, ilus
Artículo en Español | LILACS | ID: lil-575589

Documentos relacionados

  1. Expanding the Substrate Scope of Acyltransferase LovD9 for the Biosynthesis of Statin Analogues.
  2. An overview on nanoplatforms for statins delivery: Perspectives for safe and effective therapy.
  3. Sterols in asthma.
  4. Boosting Immunity by Targeting Post-translational Prenylation of Small GTPases.
  5. Genuine versus bogus scientific controversies: the case of statins.
  6. National Trends in Statin Use in Lithuania from 2010 to 2021.
  7. Maximizing Benefits and Minimizing Adverse Effects of Statins.
  8. Discovery of Natural Potent HMG-CoA Reductase Degraders for Lowering Cholesterol.
  9. How Will Our Practice Change After the CLEAR Outcomes Trial?
  10. Using the Practical Robust Implementation and Sustainability Model (PRISM) to Identify and Address Provider-Perceived Barriers to Optimal Statin Prescribing and Use in Community Health Centers.